| ProShares Ultra Nasdaq Biotechnology ETF (the "Fund") is an open-end management investment company. The Fund seeks daily investment results, before fees and expenses, that correspond to two times the inverse (–2x) of the daily performance of the NASDAQ Biotechnology Index® (the "Index"). The Index is a modified capitalization-weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark which also meet other eligibility criteria determined by NASDAQ. As of May 31 2013, the Fund's total assets were $112,166,575 and the Fund's investment portfolio was valued at $101,557,383. We show 414 historical shares outstanding datapoints in our BIB shares outstanding history coverage, used to compute BIB market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BIB market cap history over the course of time is important for investors
interested in comparing BIB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BIB versus a peer is one thing; comparing
BIB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BIB can fluctuate over the course of history.
With this page we aim to empower investors researching BIB by allowing them to research the BIB market cap history.